SEC Form 4 · accession 0000899243-19-002093
Epizyme, Inc. · EPZM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew Ros
Officer — Chief Operating Officer
Period of report
Jan 24, 2019
Accepted (ET)
Jan 28, 2019 · 8:18 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001571498
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 24, 2019 | A | 32,894 | $0.00 | A | 36,217 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $9.12 | Jan 24, 2019 | A | 151,620 | A | — | Jan 23, 2029 | Common Stock | 151,620 | 151,620 | D |
Explanation of responses
- F1Consists of shares of Common Stock issuable under 32,894 restricted stock units ("RSUs") granted pursuant to the Company's 2013 Stock Incentive Plan. Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in four equal annual installments over four years from the grant date, with the first installment vesting on January 24, 2020
- F2This option was granted on January 24, 2019 pursuant to the Company's 2013 Stock Incentive Plan with respect to 151,620 shares of Common Stock, with 25% vesting on January 24, 2020 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter.
Remarks
Exhibit Index: 24 Power of Attorney